U.S. markets closed

Jiangsu Hengrui Medicine Co., Ltd. (600276.SS)

Shanghai - Shanghai Delayed Price. Currency in CNY
Add to watchlist
79.99-2.13 (-2.59%)
At close: 3:00PM CST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close82.12
Open82.12
Bid79.99 x 0
Ask80.00 x 0
Day's Range79.99 - 82.35
52 Week Range77.33 - 116.87
Volume37,105,386
Avg. Volume33,846,167
Market Cap426.484B
Beta (5Y Monthly)0.37
PE Ratio (TTM)64.93
EPS (TTM)1.23
Earnings DateJul 30, 2021 - Aug 03, 2021
Forward Dividend & Yield0.19 (0.24%)
Ex-Dividend DateMay 25, 2020
1y Target Est73.49
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Reuters

      Stymied at home, Korea's mom and pop investors charge into China tech stocks

      South Korean retail investors are stampeding into Chinese stocks in record numbers, ploughing hundreds of millions of dollars into a tech sector rush far removed from punishing taxes and regulations on investment at home. In July alone, South Korean investors spent $240 million buying shares in mainland China, data from the Korea Securities Depository (KSD) showed - their largest investment in mainland markets on record.